KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 100,000 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average price of $9.23 per share, with a total value of $923,000.00. Following the completion of the acquisition, the insider now directly owns 5,217,285 shares of the company’s stock, valued at $48,155,540.55. This represents a 1.95 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par acquired 4,137 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.14 per share, with a total value of $37,812.18.
• On Friday, February 7th, Venrock Healthcare Capital Par acquired 73,649 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.29 per share, with a total value of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $9.76 on Friday. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $16.88. The company has a market capitalization of $482.32 million, a PE ratio of -2.68 and a beta of 0.85. The company has a 50-day simple moving average of $8.75 and a two-hundred day simple moving average of $10.54.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. On average, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Finally, JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $23.80.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Suvretta Capital Management LLC grew its stake in shares of KalVista Pharmaceuticals by 0.5% during the third quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock worth $48,775,000 after acquiring an additional 20,000 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after acquiring an additional 1,700,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock worth $19,102,000 after acquiring an additional 104,716 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $13,467,000. Finally, State Street Corp grew its stake in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after acquiring an additional 515,179 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).